Published on December 10, 2009 at 4:50 AM
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc.
(Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), unveiled
plans for an educational webinar about microRNA biology that will
highlight several recent exciting discoveries in the field and showcase
the therapeutic strategies based on microRNA.
The webinar, scheduled for 3:00 p.m. EST on Monday, December 14, 2009,
will feature two leading researchers in the field of microRNA biology:
-
Tom Tuschl, Ph.D., Professor at the Rockefeller University heading the
Laboratory of RNA Molecular Biology and a Howard Hughes Medical
Institute investigator, will discuss advances in microRNA discovery
and highlight recent scientific advances from the Tuschl laboratory;
and
-
Markus Stoffel, MD, Ph.D., Professor at the Swiss Federal Institute of
Technology, Institute of Molecular Systems Biology will discuss
microRNA therapeutic strategies and highlight recent scientific
advances from the Stoffel laboratory.
The discussion will be moderated by Kleanthis G. Xanthopoulos, Ph.D.,
President and CEO of Regulus Therapeutics Inc, a company leading the
development of a novel class of high impact medicines that target
microRNA.
“The body of knowledge about microRNA is growing exponentially, and
there have been several significant advances in the field over the last
twelve months,” said Dr. Xanthopoulos. “This educational webinar, geared
toward scientists, members of the media, and the investment community,
will serve as an update on the latest discoveries, as well as provide
insight into how they might be translated into the medicines of
tomorrow.”
http://www.regulusrx.com/
c73fdfdd-21e4-4d2f-bda4-f064c7a0a5ef|0|.0
Posted in: Medical Science News
Tags: Antisense, Cancer, Cardiovascular Disease, Cell, Fibrosis, Gene Expression, Heart Failure, Hepatitis C, Hypercholesterolemia, Immunology, Investment, Metabolism, microRNA, Molecular Biology, Oligonucleotides, Oncology, RNA, RNAi Therapeutics, Stem Cell, Virus